SLAM
TEVA icon

Swiss Life Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Swiss Life Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Buy
126,338
+24,348
+24% +$811K 0.02% 486
2026
Q1 		$3.07M Buy
101,990
+5,497
+6% +$177K 0.02% 493
2025
Q4 		$3.01M Sell
96,493
-38,849
-29% -$957K 0.02% 498
2025
Q3 		$2.73M Sell
135,342
-5,047
-4% -$88.6K 0.01% 515
2025
Q2 		$2.35M Buy
140,389
+47,738
+52% +$770K 0.01% 531
2025
Q1 		$1.42M Buy
92,651
+16,532
+22% +$295K 0.01% 561
2024
Q4 		$1.68M Buy
+76,119
New +$1.38M 0.01% 503
2017
Q2 		– Sell
-19,905
Closed -$639K – 480
2017
Q1 		$639K Buy
+19,905
New +$679K 0.02% 366
2016
Q2 		– Sell
-3,979
Closed -$213K – 378
2016
Q1 		$213K Sell
3,979
-155
-4% -$9.1K 0.01% 342
2015
Q4 		$271K Buy
+4,134
New +$255K 0.01% 286

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss Life Asset Management's TEVA Position: Q2 2026 in Review

Swiss Life Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 24% in Q2 2026, buying an estimated $811K and bringing the position to 126,338 shares worth $4.28M. The position accounts for 0.02% of the portfolio, ranked #486.

Swiss Life Asset Management first reported a position in TEVA in Q4 2015 and has held it in 10 quarters since. 451 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Swiss Life Asset Management held 126,338 shares of Teva Pharmaceuticals worth $4.28M as of Q2 2026.
  • Swiss Life Asset Management bought 24,348 Teva Pharmaceuticals shares in Q2 2026, an estimated $811K.
  • Teva Pharmaceuticals made up 0.02% of Swiss Life Asset Management's portfolio in Q2 2026, its #486 holding.
  • Swiss Life Asset Management first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 10 quarters since.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.